This HTML5 document contains 80 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00292/identifier/kegg-compound/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00292/identifier/bindingdb/
n17http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n4http://linked.opendata.cz/resource/drugbank/company/
n5http://linked.opendata.cz/resource/drugbank/dosage/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00292/identifier/kegg-drug/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00292/identifier/drugbank/
n26http://bio2rdf.org/drugbank:
n18http://linked.opendata.cz/resource/drugbank/drug/DB00292/identifier/national-drug-code-directory/
admshttp://www.w3.org/ns/adms#
n11http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n6http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n16http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n23http://www.drugs.com/cdi/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00292/identifier/chebi/
n9http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n24http://linked.opendata.cz/resource/drugbank/drug/DB00292/identifier/pharmgkb/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00292/identifier/wikipedia/
n8http://linked.opendata.cz/resource/atc/
n7http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00292
rdf:type
n3:Drug
n3:description
Imidazole derivative anesthetic and hypnotic with little effect on blood gases, ventilation, or the cardiovascular system. It has been proposed as an induction anesthetic. [PubChem]
n3:dosage
n5:271B4BBD-363D-11E5-9242-09173F13E4C5 n5:271B4BBE-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
75 minutes.
n3:indication
Used in the induction of general anesthesia.
n3:manufacturer
n4:271B4BB8-363D-11E5-9242-09173F13E4C5 n4:271B4BB6-363D-11E5-9242-09173F13E4C5 n4:271B4BB9-363D-11E5-9242-09173F13E4C5 n4:271B4BB7-363D-11E5-9242-09173F13E4C5
owl:sameAs
n11:DB00292 n26:DB00292
dcterms:title
Etomidate
adms:identifier
n13:50125938 n14:4910 n15:D00548 n18:0409-6695-01 n19:DB00292 n20:C07522 n21:Etomidate n24:PA164743987
n3:mechanismOfAction
Etomidate binds at a distinct binding site associated with a Cl<sup>-</sup> ionopore at the GABA<sub>A</sub> receptor, increasing the duration of time for which the Cl<sup>-</sup> ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged.
n3:packager
n4:271B4BB3-363D-11E5-9242-09173F13E4C5 n4:271B4BB4-363D-11E5-9242-09173F13E4C5 n4:271B4BB1-363D-11E5-9242-09173F13E4C5 n4:271B4BB2-363D-11E5-9242-09173F13E4C5 n4:271B4BB5-363D-11E5-9242-09173F13E4C5 n4:271B4BB0-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
Approximately 75% of the administered dose is excreted in the urine during the first day after injection.
n3:synonym
3-((R)-1-Phenyl-ethyl)-3H-imidazole-4-carboxylic acid ethyl ester R-(+)-Ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate (R)-1-(1-phenylethyl)-1H-imidazole-5-carboxylic acid ethyl ester (R)-(+)-1-(alpha-Methylbenzyl)imidazole-5-carboxylic acid ethyl ester (+)-ethyl 1-(α-methylbenzyl)imidazole-5-carboxylate (+)-Ethyl 1-(alpha-methylbenzyl)imidazole-5-carboxylate Etomidate Etomidato Etomidatum (+)-etomidate
n3:toxicity
Undesirable side effects of etomidate that may limit its use include pain on injection, myoclonus and adrenocortical suppression lasting 4-6 hours following an induction dose.
n3:proteinBinding
76%, primarily to serum albumin.
n3:synthesisReference
Douglas E. Raines, "ETOMIDATE ANALOGUES THAT DO NOT INHIBIT ADRENOCORTICAL STEROID SYNTHESIS." U.S. Patent US20130079381, issued March 28, 2013.
n16:hasConcept
n17:M0007928
foaf:page
n23:etomidate.html
n3:IUPAC-Name
n9:271B4BC3-363D-11E5-9242-09173F13E4C5
n3:InChI
n9:271B4BC9-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n9:271B4BC8-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n9:271B4BC5-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n9:271B4BC6-363D-11E5-9242-09173F13E4C5
n3:SMILES
n9:271B4BC7-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n9:271B4BC1-363D-11E5-9242-09173F13E4C5 n9:271B4BD8-363D-11E5-9242-09173F13E4C5
n3:logP
n9:271B4BBF-363D-11E5-9242-09173F13E4C5 n9:271B4BC2-363D-11E5-9242-09173F13E4C5 n9:271B4BDA-363D-11E5-9242-09173F13E4C5
n3:logS
n9:271B4BC0-363D-11E5-9242-09173F13E4C5
n7:hasATCCode
n8:N01AX07
n3:H-Bond-Acceptor-Count
n9:271B4BCF-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n9:271B4BD0-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n9:271B4BCA-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n9:271B4BCB-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n9:271B4BCD-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n9:271B4BCC-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n9:271B4BCE-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
33125-97-2
n3:category
n3:containedIn
n6:271B4BBA-363D-11E5-9242-09173F13E4C5 n6:271B4BBB-363D-11E5-9242-09173F13E4C5 n6:271B4BBC-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n9:271B4BD4-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n9:271B4BD6-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n9:271B4BD7-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n9:271B4BD9-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n9:271B4BD3-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n9:271B4BD2-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n9:271B4BD5-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n9:271B4BC4-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n9:271B4BD1-363D-11E5-9242-09173F13E4C5